Physician profile
Ryan S Beard
NPI 1962658021
$19,031.33
in general payments reported to CMS, 2019-2025
38 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,629 · 2020: $1,283 · 2021: $3,720 · 2022: $1,072 · 2023: $773 · 2024: $7,380 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Travel and Lodging: $4,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,394.66 |
| Travel and Lodging | $4,931.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,197.84 | 2021-2025 | Micra, Symplicity G3, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $4,235.46 | 2020-2025 | Aveir, Assurity, Optis |
| Medtronic Vascular, INC. | $1,443.59 | 2019-2020 | |
| Penumbra, INC. | $1,082.08 | 2025 | Indigo System, Penumbra System |
| Astrazeneca Pharmaceuticals Lp | $787.25 | 2019-2024 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $749.24 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $706.18 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $674.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $576.17 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $527.77 | 2020-2024 | Avvigo Guidance System |
| Biotronik INC. | $323.42 | 2019-2020 | |
| Amgen INC. | $256.84 | 2019-2025 | Repatha |
| Shockwave Medical, INC | $182.07 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amarin Pharma, INC. | $160.35 | 2019-2022 | |
| Inari Medical, INC. | $106.70 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.38 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.22 | 2019-2025 | Lifevest |
| Endologix LLC | $95.65 | 2024 | Torus Stent Graft System, Endocross Device |
| Pfizer INC. | $80.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.66 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $69.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.23 | 2024-2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $58.35 | 2023 | Arcalyst |
| Lundbeck LLC | $55.19 | 2019-2020 | |
| United Therapeutics Corporation | $46.22 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $42.10 | 2020-2021 | |
| Bardy Diagnostics, INC. | $36.95 | 2020 | |
| Gilead Sciences, INC. | $27.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.97 | 2021 | |
| Surmodics, INC. | $23.03 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Pounce Thrombectomy System |
| Edwards Lifesciences Corporation | $21.00 | 2025 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $19.20 | 2019 | |
| My01 INC. | $17.87 | 2025 | My01 Continuous Compartmental Pressure Monitor |
| Abiomed | $13.86 | 2022 | |
| Irhythm Technologies, INC. | $13.66 | 2019 | |
| Preventice Services, LLC | $13.64 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $10.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.